Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Voriconazole (ZP-059) in Healthy and Asthmatic Subjects
NCT04229303Phase 1Completed
- Sponsor
- Zambon
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZP-059 in allergic bronchopulmonary aspergillosis (ABPA) (9 arms), sponsored by Zambon. Primary endpoint: Treatment-Emergent Adverse Events. Started Feb 2020; status: completed.
02
Drugs
ZP-059
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT04229303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229303.